Upregulation of T-cell Immunoglobulin and Mucin-Domain Containing-3 (Tim-3) in Monocytes/Macrophages Associates with Gastric Cancer Progression

References

• Anderson AC, Anderson DE, Bregoli L, et al. (2007). Promotion of tissue inflammation by the immune receptor TIM-3 expressed on innate immune cells. Science, 318, 1141–1143.
   PubMed Web of Science ®Google Scholar
• Anderson AC, Lord GM, Dardalhon V, et al. (2010). T-bet, a Th1 transcription factor regulates the expression of Tim-3. Eur J Immunol, 40(3), 859–866.
   PubMed Web of Science ®Google Scholar
• Azimi, F. Scolyer RA, Rumcheva P, et al. (2012). Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma. J Clin Oncol, 30, 2678–2683.
   PubMed Web of Science ®Google Scholar
• Cai C, Zhang J, Li M, et al. (2016). Jun Interleukin 10-expressing B cells inhibit tumor-infiltrating T cell function and correlate with T cell Tim-3 expression in renal cell carcinoma. Tumour Biol, 37(6), 8209–8218.
   PubMed Web of Science ®Google Scholar
• Chanmee T, Ontong P, Konno K, Itano N. (2014). Tumor-associated macrophages as major players in the tumor microenviroment. Cancers (Basel), 6(3), 1670–1690.
   PubMed Web of Science ®Google Scholar
• Cheng P, Kumar V, Liu H, et al. (2014). Effects of notch signaling on regulation of myeloid cell differentiation in cancer. Cancer Res, 74(1), 141–152.
   PubMed Web of Science ®Google Scholar
• De Palma M, Lewis CE. (2011). Cancer: Macrophages limit chemotherapy. Nature, 472(7343), 303–304.
   PubMed Web of Science ®Google Scholar
• Frisullo G, Angelucci F, Caggiula M, et al. (2006). pSTAT1, pSTAT3, and T-bet expression in peripheral blood mononuclear cells from relapsing-remitting multiple sclerosis patients correlates with disease activity. J Neurosci Res, 84(5), 1027–1036.
   PubMed Web of Science ®Google Scholar
• Fukuda K, Kobayashi A, Watabe K. (2012). The role of tumor-associated macrophage in tumor progression. Front Biosci (School Ed), 4, 787–798.
   PubMedGoogle Scholar
• Galon J, Costes A, Sanchez-Cabo F, et al. (2006). Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science, 313, 1960–1964.
   PubMed Web of Science ®Google Scholar
• Gao X, Zhu Y, Li G, et al. (2012). TIM-3 expression characterizes regulatory T cells in tumor tissues and is associated with lung cancer progression. Plos One, 7(2), e30676.
   PubMed Web of Science ®Google Scholar
• González CA, Sala N, Rokkas T. (2013). Gastric cancer: Epidemiologic aspects. Helicobacter, 18(Supplement 1), 34–38.
   Web of Science ®Google Scholar
• Hastings WD, Anderson DE, Kassam N, et al. (2009). TIM-3 is expressed on activated human CD4(+) T cells and regulates Th1 and Th17 cytokines. Eur J Immunol, 39(9), 2492–501.
   PubMed Web of Science ®Google Scholar
• Jemal A, Bray F, Center MM, et al. (2011). Global Cancer Statistics. CA Cancer J Clin, 61, 69–90.
   PubMed Web of Science ®Google Scholar
• Jennifer C. (2013). Breakthrough of the year: Cancer immunotherapy. Science, 342(6165), 1432–1433.
   PubMed Web of Science ®Google Scholar
• Kemp RA, Ronchese F. (2001). Tumor-specific Tc1, but not Tc2, cells deliver protective antitumor immunity. J Immunol, 167(11), 6497–6502.
   PubMed Web of Science ®Google Scholar
• Lee YY, Derakhshan MH. (2013). Environmental and lifestyle risk factors of gastric cancer. Arch Iran Med, 16, 358–365.
   PubMed Web of Science ®Google Scholar
• Li S, Wan J, Anderson W, Sun H, et al. (2016). Downregulation of IL-10 secretion by Treg cells in osteoarthritis is associated with a reduction in Tim-3 expression. Biomed Pharmacother, 79, 159–165.
   PubMed Web of Science ®Google Scholar
• Mahoney KM, Rennert PD, Freeman GJ. (2015). Combination cancer immunotherapy and new immunomodulatory targets. Nat Rev Drug Discov, 14(8), 561–84.
   PubMed Web of Science ®Google Scholar
• Matsushita H, Vesely MD, Koboldt DC, et al. (2012). Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature, 482, 400–404.
   PubMed Web of Science ®Google Scholar
• McIntire JJ, Umetsu SE, Akbari O, et al. (2001). Identification of Tapr (an airway hyperreactivity regulatory locus) and the linked TIM genefamily. Nat Immunol, 2(12), 1109–1116.
   PubMed Web of Science ®Google Scholar
• Meza-Junco J, Au HJ, Sawyer MB. (2011). Critical appraisal of trastuzumab in treatment of advanced stomach cancer. Cancer Manag, Res, 57–64.
   Google Scholar
• Monney L. (2002). Th1-specific cell surfaceprotein TIM-3 regulates macrophage activation and severity of an autoimmune disease. Nature, 415, 536–541.
   PubMed Web of Science ®Google Scholar
• Nakae S, Iikura M, Suto H, et al. (2007). TIM-1 and TIM-3 enhancement of Th2 cytokine production by mast cells. Blood, 110, 2565–2568.
   PubMed Web of Science ®Google Scholar
• Orditura M, Galizia G, Sforza V, et al. (2014). Treatment of gastric cancer. World J Gastroenterol 20, 1635–1649.
   PubMed Web of Science ®Google Scholar
• Petronela Ancuta, Kuang-Yu Liu, Vikas Misra, et al. (2009). Transcriptional profiling reveals developmental relationship and distinct biological functions of CD16+ and CD16- monocyte subsets. BMC Genomics, 10, 403.
   Web of Science ®Google Scholar
• Raetz CR, Whitfield C. (2002). Lipopolysaccharide endotoxins. Ann Rev Biochem, 71, 635–700.
   PubMed Web of Science ®Google Scholar
• Rittig MG, Kaufmann A, Robins A, et al. (2003). Smooth and rough lipopolysaccharide phenotypes of Brucella induce different intracellular trafficking and cytokine/chemokine release in human monocytes. J Leukoc Biol, 74, 1045–1055.
   PubMed Web of Science ®Google Scholar
• Ruffell B, Affara NI, Coussens LM. (2012). Differential macrophage programming in the tumor microenvironment. Trends Immunol, 33(3), 119–126.
   PubMed Web of Science ®Google Scholar
• Rusakiewicz S, Semeraro M, Sarabi M, et al. (2013). Immune infiltrates are prognostic factors in localized gastrointestinal stromal tumors. Cancer Res, 73, 3499–3510.
   PubMed Web of Science ®Google Scholar
• Sabatos CA, Chakravarti S, Cha E, et al. (2010). Interaction of TIM-3 and TIM-3 ligand regulates T helper type1 response and induction of peripheral tolerance. Nat Immunol, 4, 1102–1110.
   Web of Science ®Google Scholar
• Sandra Demaria, Eli Pikarsky, Michael Karin, et al. (2010). Cancer and inflammation: Promise for biological therapy. J Immunother, 33(4), 335–351.
   PubMed Web of Science ®Google Scholar
• Seton-Rogers S. (2013). Tumour microenvironment: Teaching old macrophages new tricks. Nat Rev Cancer, 13(11), 753.
   PubMed Web of Science ®Google Scholar
• Sica A, Mantovani A. (2012). Macrophage plasticity and polarization: In vivo veritas. J Clin Invest, 122(3), 787–7895.
   PubMed Web of Science ®Google Scholar
• Stefater JA 3rd, Lewkowich I, Rao S, et al. (2011). Regulation of angiogenesis by a non-canonical Wnt-Flt1 pathway in myeloid cells. Nature, 474(7352), 511–515.
   Google Scholar
• Szabo SJ, Kim ST, Costa GL, et al. (2000). A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell, 100, 655–669.
   PubMed Web of Science ®Google Scholar
• Thompson ED, Enriquez HL, Fu YX, Engelhard VH. (2010). Tumor masses support naive T cell infiltration, activation, and differentiation into effectors. J Exp Med, 207, 1791–804.
   PubMed Web of Science ®Google Scholar
• Tosolini M, Kirilovsky A, Mlecnik B, et al. (2011). Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer. Cancer Res, 71(4), 1263–1271.
   PubMed Web of Science ®Google Scholar
• Umansky V, Sevko A. (2013). Tumor microenvironment and myeloid-derived suppressor cells. Cancer Microenviron, 6(2), 169–177.
   PubMedGoogle Scholar
• Wang Z, Zhu J, Gu H, et al. (2015). The clinical significance of abnormal Tim-3 expression on NK cells from patients with gastric cancer. Immunol Invest, 44(6), 578–589.
   PubMed Web of Science ®Google Scholar
• Zhang G, Huang H, Zhu Y, et al. (2015). A novel subset of B7-H3+CD14+HLA-DR-/low myeloid-derived suppressor cells are associated with progression of human NSCLC. OncoImmunology, 4(02), e977164.
   PubMed Web of Science ®Google Scholar
• Zhu C, Anderson AC, Schubart A, et al. (2005). The TIM-3 ligand galectin-9 negatively regulates T helper type1 immunity. Nat Immunol, 6(12), 1245–1252.
   PubMed Web of Science ®Google Scholar